iRhythm(US:IRTC) Globenewswireยท2025-06-23 12:30Core Insights - iRhythm Technologies, Inc. presented findings indicating that cardiac arrhythmias are prevalent and often occur early in patients with type 2 diabetes (T2D), particularly those with chronic kidney disease (CKD), suggesting a need for improved early detection strategies in at-risk populations [1][5][11] Group 1: Study Findings - The studies analyzed longitudinal claims data from over 30 million U.S. adults, revealing that arrhythmias frequently appear before or shortly after diagnoses of CKD or major adverse cardiovascular events (MACE) in T2D patients [2][10] - In a cohort of 8.8 million T2D individuals, over 1.1 million were diagnosed with major arrhythmias, with 47% occurring after diabetes diagnosis and a median time of 496 days to arrhythmia detection [8][10] - Among 3.2 million T2D patients who received a CKD diagnosis, 670,003 (21%) developed major arrhythmias, with 59% of these occurring before CKD diagnosis [8][11] Group 2: Clinical Implications - Cardiac arrhythmias are a significant public health concern, affecting approximately 1 in 20 adults in the general U.S. population, but are more frequent and earlier in T2D and CKD patients [3][4] - Early detection of arrhythmias is critical as undetected conditions can lead to severe complications such as stroke, heart failure, and hospitalization [4][9] - The findings emphasize the importance of monitoring patients based on unique risk factors rather than solely on symptoms, as fewer than one in five patients experience symptoms during arrhythmic episodes [9][10] Group 3: Recommendations for Future Research - The studies suggest a need for innovative diagnostic approaches, including continuous ambulatory EKG monitoring, to facilitate early intervention and precision therapies for patients with T2D and CKD [11][12] - Further investigations are warranted to explore strategies for early diagnosis, risk stratification, and intervention in patients at risk of arrhythmias and MACE [10][11]